TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1/Line 1-5	Title/Paragraph 1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome,statistical analysis, results, and conclusions.	page 2-3/Line 69-91	Abstract/Paragraph 1-4
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	page 3-4/Line 98-143	Introduction/Paragraph 1-3
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	page 4/Line 144-146	Introduction/Paragraph 4
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation datasets, if applicable.	page 4/Line 150-152	Materials and Methods/ Paragraph 1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	N/A (This is a multicentre retrospective study)	N/A (This is a multicentre retrospective study)
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	page 4/Line 150-160	Materials and Methods/ Paragraph 1
	5b	D;V	Describe eligibility criteria for participants.	page 4-5/Line 160-167	Materials and Methods/ Paragraph 1
	5c	D;V	Give details of treatments received, if relevant.	N/A (This is a retrospective observational study)	N/A (This is a retrospective observational study)
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	page 5/Line 169-176	Materials and Methods/ Paragraph 2

	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	page 5/Line 199-200	Materials and Methods/ Paragraph 5
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	a. page 5/Line 178-185 b. page 5-6/ Line 203-219	a. Materials and Methods / Paragraph 3 b. Materials and Methods / Paragraph 6-7
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	page 5/Line 193-199	Materials and Methods/ Paragraph 5
Sample size	8	D;V	Explain how the study size was arrived at.	page 6/Line 227-231	Materials and Methods/ Paragraph 8

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	N/A (This is a retrospective observational study)	N/A (This is a retrospective observational study)
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	page 6/Line 221-227	Materials and Methods/ Paragraph 8
	10b	D	Specify type of model, all model-building procedures (including any predictor selection),and method for internal validation.	page 6/Line 233-240	Materials and Methods/ Paragraph 9
	10c	V	For validation, describe how the predictions were calculated.	page 6/Line 239-240	Materials and Methods/ Paragraph 9
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	page 7/Line 260-262	Materials and Methods/ Paragraph 13
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A(This is a retrospective study and the constructed model was not validated in prospective data)	N/A(This is a retrospective study and the constructed model was not validated in prospective data)
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	page 6/Line 241-244	Materials and Methods/ Paragraph 10
Development vs. validation	12	V	For validation, identify any differences from the development data insetting, eligibility criteria, outcome, and predictors.	page 7/Line 265-266	Results/Paragraph 1
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	page 7/Line 265-266	Results/Paragraph 1
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	page 7/Line 265-266	Results/Paragraph 1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	page 7/Line 265-266	Results/Paragraph 1
Model	14a	D	Specify the number of participants and outcome events in each analysis.	page 7/Line 265-266	Results/Paragraph 1

development	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	N/A (This was not carried out)	N/A (This was not carried out)
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	page 8/Line 298-301	Results/Paragraph 4
	15b	D	Explain how to the use the prediction model.	page 8/Line 309-310	Results/Paragraph 5
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	page 8/Line 301-308	Results/Paragraph 4
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A(This is a retrospective study and the constructed model was not validated in prospective data)	N/A(This is a retrospective study and the constructed model was not validated in prospective data)
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	page 9-10/Line 373-380	Discussion/ Paragraph 5

Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	page 8/Line 317-321	Discussion/ Paragraph 1
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	page 8-9/Line 326-342	Discussion/ Paragraph 2
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	page 10/Line 385-387	Conclusions/ Paragraph 1
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and datasets.		Supplementary Material
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.		Acknowledgments

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: https://dx.doi.org/10.21037/qims-23-807

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.